112 related articles for article (PubMed ID: 19269221)
21. Identification of a novel mutation in the ryanodine receptor gene (RYR1) in a malignant hyperthermia Italian family.
Fortunato G; Berruti R; Brancadoro V; Fattore M; Salvatore F; Carsana A
Eur J Hum Genet; 2000 Feb; 8(2):149-52. PubMed ID: 10757649
[TBL] [Abstract][Full Text] [Related]
22. A variable myopathy associated with heterozygosity for the R503C mutation in the carnitine palmitoyltransferase II gene.
Vladutiu GD; Bennett MJ; Smail D; Wong LJ; Taggart RT; Lindsley HB
Mol Genet Metab; 2000 Jun; 70(2):134-41. PubMed ID: 10873395
[TBL] [Abstract][Full Text] [Related]
23. Toxicological and histopathological analysis of a patient who died nine days after a single intravenous dose of methamphetamine: a case report.
Ago M; Ago K; Hara K; Kashimura S; Ogata M
Leg Med (Tokyo); 2006 Jul; 8(4):235-9. PubMed ID: 16793314
[TBL] [Abstract][Full Text] [Related]
24. The application of immunohistochemical findings in the diagnosis in methamphetamine-related death-two forensic autopsy cases-.
Ishigami A; Kubo S; Gotohda T; Tokunaga I
J Med Invest; 2003 Feb; 50(1-2):112-6. PubMed ID: 12630576
[TBL] [Abstract][Full Text] [Related]
25. No carnitine palmitoyltransferase deficiency in skeletal muscle in 18 malignant hyperthermia susceptible individuals.
Wieser T; Kraft B; Kress HG
Neuromuscul Disord; 2008 Jun; 18(6):471-4. PubMed ID: 18430572
[TBL] [Abstract][Full Text] [Related]
26. Autopsy case of the neonatal form of carnitine palmitoyltransferase-II deficiency triggered by a novel disease-causing mutation del1737C.
Semba S; Yasujima H; Takano T; Yokozaki H
Pathol Int; 2008 Jul; 58(7):436-41. PubMed ID: 18577113
[TBL] [Abstract][Full Text] [Related]
27. Minicore myopathy with ophthalmoplegia caused by mutations in the ryanodine receptor type 1 gene.
Jungbluth H; Zhou H; Hartley L; Halliger-Keller B; Messina S; Longman C; Brockington M; Robb SA; Straub V; Voit T; Swash M; Ferreiro A; Bydder G; Sewry CA; Müller C; Muntoni F
Neurology; 2005 Dec; 65(12):1930-5. PubMed ID: 16380615
[TBL] [Abstract][Full Text] [Related]
28. Identification and biochemical characterization of a novel ryanodine receptor gene mutation associated with malignant hyperthermia.
Anderson AA; Brown RL; Polster B; Pollock N; Stowell KM
Anesthesiology; 2008 Feb; 108(2):208-15. PubMed ID: 18212565
[TBL] [Abstract][Full Text] [Related]
29. A fulminant malignant hyperthermia episode in a patient with ryanodine receptor gene mutation p.Tyr522Ser.
Girard T; Suhner M; Levano S; Singer M; Zollinger A; Hofer CK
Anesth Analg; 2008 Dec; 107(6):1953-5. PubMed ID: 19020143
[TBL] [Abstract][Full Text] [Related]
30. Central core disease is due to RYR1 mutations in more than 90% of patients.
Wu S; Ibarra MC; Malicdan MC; Murayama K; Ichihara Y; Kikuchi H; Nonaka I; Noguchi S; Hayashi YK; Nishino I
Brain; 2006 Jun; 129(Pt 6):1470-80. PubMed ID: 16621918
[TBL] [Abstract][Full Text] [Related]
31. Muscle carnitine palmitoyltransferase II deficiency: clinical and molecular genetic features and diagnostic aspects.
Deschauer M; Wieser T; Zierz S
Arch Neurol; 2005 Jan; 62(1):37-41. PubMed ID: 15642848
[TBL] [Abstract][Full Text] [Related]
32. Endovascular cooling in a patient with neuroleptic malignant syndrome.
Diedler J; Mellado P; Veltkamp R
J Neurol Sci; 2008 Jan; 264(1-2):163-5. PubMed ID: 17706678
[TBL] [Abstract][Full Text] [Related]
33. Functional characterization of malignant hyperthermia-associated RyR1 mutations in exon 44, using the human myotube model.
Wehner M; Rueffert H; Koenig F; Olthoff D
Neuromuscul Disord; 2004 Jul; 14(7):429-37. PubMed ID: 15210166
[TBL] [Abstract][Full Text] [Related]
34. [Rhabdomyolysis and myoglobinuria].
Lindner A; Zierz S
Nervenarzt; 2003 Jun; 74(6):505-15. PubMed ID: 12799789
[TBL] [Abstract][Full Text] [Related]
35. [Acute rhabdomyolysis: a case report and literature review].
Mrsić V; Nesek Adam V; Grizelj Stojcić E; Rasić Z; Smiljanić A; Turcić I
Acta Med Croatica; 2008 Jul; 62(3):317-22. PubMed ID: 18843854
[TBL] [Abstract][Full Text] [Related]
36. [Acute renal failure in neuroleptic malignant syndrome].
Wagner G; Rónai L
Orv Hetil; 1995 Oct; 136(40):2173-6. PubMed ID: 7566952
[TBL] [Abstract][Full Text] [Related]
37. Genetic risk factors associated with lipid-lowering drug-induced myopathies.
Vladutiu GD; Simmons Z; Isackson PJ; Tarnopolsky M; Peltier WL; Barboi AC; Sripathi N; Wortmann RL; Phillips PS
Muscle Nerve; 2006 Aug; 34(2):153-62. PubMed ID: 16671104
[TBL] [Abstract][Full Text] [Related]
38. Novel ryanodine receptor mutation that may cause malignant hyperthermia.
Kaufmann A; Kraft B; Michalek-Sauberer A; Weigl LG
Anesthesiology; 2008 Sep; 109(3):457-64. PubMed ID: 18719443
[TBL] [Abstract][Full Text] [Related]
39. Recurrent post-infectious rhabdomyolysis in muscle CPT-II deficiency caused by a novel missense mutation.
van den Ameele J; Van Landegem W; Wuyts W; De Bleecker J
Acta Neurol Belg; 2008 Dec; 108(4):155-60. PubMed ID: 19239046
[TBL] [Abstract][Full Text] [Related]
40. Severe hyponatremia, neuroleptic malignant syndrome, rhabdomyolysis and acute renal failure: a case report.
Elizalde-Sciavolino C; Racco A; Proscia-Lieto T; Kleiner M
Mt Sinai J Med; 1998 Sep; 65(4):284-8. PubMed ID: 9757749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
